PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Afshar‐Oromieh, Ali; Malcher, A.; Eder, Matthias; Eisenhut, Michael; Linhart, Heinz; Hadaschik, Boris; Holland‐Letz, Tim; Giesel, Frederik L.; Kratochwil, Clemens; Haufe, Sabine; Haberkorn, Uwe; Zechmann, Christian M.

doi:10.1007/s00259-012-2298-2

Cited by 808 publications

(673 citation statements)

References 13 publications

Supporting

Mentioning

611

Contrasting

Unclassified

Order By: Relevance

“…68 Ga-PSMA-HBED-CC has been compared to 11 Cfluoromethylcholine in the diagnosis of PC and has been found to be more sensitive in the diagnosis of lymph node, central bone, and liver metastases [9]. Biodistribution studies have revealed uptake of the radiotracer in the lacrimal glands, salivary glands, liver, spleen, kidneys, small and large bowel besides lesions suspicious for PC [10]. Atypical uptake of this tracer has been reported in the celiac ganglion mimicking lymph nodes [11].…”

Section: Discussionmentioning

confidence: 99%

Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule

Damle

Tripathi

Chakraborty

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

68 Ga-Prostate specific membrane antigen-N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N ′-diacetic acid-positron emission tomography/computed tomography or 68 Ga-HBED-CC-PSMA PET/CT, popularly known as PSMA PET/CT, is able to detect a small volume of recurrent prostate carcinoma (PC) when there is a prostate specific antigen (PSA) rise on follow-up after prostatectomy or other definitive treatment for PC. The use of PSMA PET/ CT in the initial staging in PC is uncertain at this time. Clinical studies are underway to define its exact role in the management of the disease. At the same time it is important to be aware of unexpected sites of uptake of this ligand. We present here the case of a 62-year-old male patient who underwent prostatectomy for adenocarcinoma prostate. He also had a long-standing left solitary thyroid nodule (STN). Four months after surgery, he had a rising trend in serum PSA levels on three occasions, but the absolute value was less than 4 at all times. He underwent a 68 Ga-PSMA-HBED-CC PET/CT, but it did not reveal any recurrent/metastatic site of disease. However, there was increased tracer uptake in the left STN.Fine needle aspiration cytology revealed features of atypia of undetermined significance, Bethesda category III. The patient underwent a left hemithyroidectomy and the histopathology showed features of a follicular adenoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Unusual Uptake of Prostate Specific Tracer 68Ga-PSMA–HBED-CC in a Benign Thyroid Nodule

Damle

Tripathi

Chakraborty

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Recently, both 18 68 Ga-PSMA have been studied in humans, and both reportedly were capable of detecting sites of metastatic prostate cancer. 125,126 In a subsequent, small clinical trial, 68 Ga-PSMA detected more lesions than 18 F-choline. 127 Somatostatin receptors are overexpressed on neuroendocrine tumor cells.…”

Section: Imaging Protein and Cell Membrane Metabolismmentioning

confidence: 94%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

194

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

“…While further studies are required to assess the efficacy of anti-3-18 F-FACBC in a larger series of prostate cancer patients, preliminary data reported by Nanni et al in this issue indicate a superiority of anti-3-18 F-FACBC over choline PET/CT in the detection of prostate cancer recurrence [9]. Although not covered in this issue, other novel investigational radiotracers such as radiolabelled prostate-specific membrane antigen [10] and bombesin analogues [11], may also have potential for clinical applications in prostate cancer.…”

Section: Other Pet Tracersmentioning

confidence: 95%